Literature DB >> 19276385

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

Yuan Rong1, Vladimir E Belozerov, Carol Tucker-Burden, Gang Chen, Donald L Durden, Jeffrey J Olson, Erwin G Van Meir, Nigel Mackman, Daniel J Brat.   

Abstract

Hypoxia and necrosis are fundamental features of glioblastoma (GBM) and their emergence is critical for the rapid biological progression of this fatal tumor; yet, underlying mechanisms are poorly understood. We have suggested that vaso-occlusion following intravascular thrombosis could initiate or propagate hypoxia and necrosis in GBM. Tissue factor (TF), the main cellular initiator of coagulation, is overexpressed in GBMs and likely favors a thrombotic microenvironment. Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas that could be responsible for TF up-regulation. The most frequent EGFR mutation in GBM involves deletion of exons 2 to 7, resulting in the expression of a constitutively active receptor, EGFRvIII. Here, we show that overexpression of EGFR or EGFRvIII in human glioma cells causes increased basal TF expression and that stimulation of EGFR by its ligand, EGF, leads to a marked dose-dependent up-regulation of TF. In all cases, increased TF expression led to accelerated plasma coagulation in vitro. EGFR-mediated TF expression depended most strongly on activator protein-1 (AP-1) transcriptional activity and was associated with c-Jun NH(2)-terminal kinase (JNK) and JunD activation. Restoration of PTEN expression in PTEN-deficient GBM cells diminished EGFR-induced TF expression by inhibiting JunD/AP-1 transcriptional activity. PTEN mediated this effect by antagonizing phosphatidylinositol 3-kinase activity, which in turn attenuated both Akt and JNK activities. These mechanisms are likely at work in vivo, as EGFR expression was highly correlated with TF expression in human high-grade astrocytoma specimens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276385      PMCID: PMC2759716          DOI: 10.1158/0008-5472.CAN-08-1547

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

Review 3.  AP-1 as a regulator of cell life and death.

Authors:  Eitan Shaulian; Michael Karin
Journal:  Nat Cell Biol       Date:  2002-05       Impact factor: 28.824

Review 4.  Molecular basis for the relationship between thrombosis and cancer.

Authors:  F R Rickles; A Falanga
Journal:  Thromb Res       Date:  2001-06-15       Impact factor: 3.944

5.  Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1.

Authors:  Udo Bavendiek; Peter Libby; Meagan Kilbride; Rebecca Reynolds; Nigel Mackman; Uwe Schönbeck
Journal:  J Biol Chem       Date:  2002-04-26       Impact factor: 5.157

6.  Elevated JNK activation contributes to the pathogenesis of human brain tumors.

Authors:  Marc A Antonyak; Lawrence C Kenyon; Andrew K Godwin; David C James; David R Emlet; Isamu Okamoto; Mehdi Tnani; Marina Holgado-Madruga; David K Moscatello; Albert J Wong
Journal:  Oncogene       Date:  2002-08-01       Impact factor: 9.867

7.  Regulation of angiogenesis by tissue factor cytoplasmic domain signaling.

Authors:  Mattias Belting; Michael I Dorrell; Staffan Sandgren; Edith Aguilar; Jasimuddin Ahamed; Andrea Dorfleutner; Peter Carmeliet; Barbara M Mueller; Martin Friedlander; Wolfram Ruf
Journal:  Nat Med       Date:  2004-04-18       Impact factor: 53.440

8.  Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.

Authors:  Igor Vivanco; Nicolaos Palaskas; Chris Tran; Stephen P Finn; Gad Getz; Norman J Kennedy; Jing Jiao; Joshua Rose; Wanling Xie; Massimo Loda; Todd Golub; Ingo K Mellinghoff; Roger J Davis; Hong Wu; Charles L Sawyers
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

9.  Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population.

Authors:  Daniel J Brat; Amilcar A Castellano-Sanchez; Stephen B Hunter; Marcia Pecot; Cynthia Cohen; Elizabeth H Hammond; Sarojini N Devi; Balveen Kaur; Erwin G Van Meir
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

Review 10.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.

Authors:  Daniel J Brat; Erwin G Van Meir
Journal:  Lab Invest       Date:  2004-04       Impact factor: 5.662

View more
  57 in total

Review 1.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

2.  Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response.

Authors:  Shannon M Gallagher-Colombo; Amanda L Maas; Min Yuan; Theresa M Busch
Journal:  Isr J Chem       Date:  2012-09-01       Impact factor: 3.333

3.  The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma.

Authors:  Lee A D Cooper; David A Gutman; Candace Chisolm; Christina Appin; Jun Kong; Yuan Rong; Tahsin Kurc; Erwin G Van Meir; Joel H Saltz; Carlos S Moreno; Daniel J Brat
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

Review 4.  Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Brain Pathol       Date:  2011-07-07       Impact factor: 6.508

5.  The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies.

Authors:  Roy E Strowd; Mary Ann Knovich; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2012-12

6.  Crosstalk between TF/FVIIa and EGFR signaling in colorectal cancer cells.

Authors:  He-Kai Chen; Xin Wang; Yuan-Lian Wan; Jian-Qiang Tang
Journal:  Cancer Biol Ther       Date:  2018-11-21       Impact factor: 4.742

7.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Authors:  Nathalie Magnus; Delphine Garnier; Brian Meehan; Serge McGraw; Tae Hoon Lee; Maxime Caron; Guillaume Bourque; Chloe Milsom; Nada Jabado; Jacquetta Trasler; Rafal Pawlinski; Nigel Mackman; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

Review 8.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

9.  TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620.

Authors:  Lichao Hu; Longfei Xia; Hong Zhou; Biao Wu; Yuan Mu; Ying Wu; Jinchuan Yan
Journal:  Tumour Biol       Date:  2013-04-25

10.  Tumors, ticks and tissue factor.

Authors:  T McEachron; N Mackman
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.